Clinical Trials

5,279 enrolled 10 charts

364 enrolled 89 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT00828919 2024-12-03

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Phase NA Completed

52 enrolled 12 charts

Other solid neoplasm

Solid Tumors

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02679170 2024-08-09

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

692 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT01712217 2024-08-02

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Phase 1/2 Completed

220 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

549 enrolled 28 charts

ALK-positive NSCLC

NCT00585195 2023-02-08

PROFILE 1001

275 enrolled 23 charts 1 FDA

596 enrolled 81 charts

Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT02737501 2021-08-20

ALTA-1L

Phase 3 Completed

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT02574078 2021-05-06

CheckMate370

Phase 1/2 Completed

341 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung

NCT01945021 2021-02-21

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Phase 2 Completed

129 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT01639001 2020-12-08

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Phase 3 Completed

207 enrolled 29 charts

Carcinoma, Non-Small-Cell Lung

NCT01999972 2020-09-24

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

50 enrolled 29 charts

Tumor-Agnostic

Carcinoma

NCT01597258 2019-09-13

Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

2,029 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT01576406 2018-10-25

Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients

88 enrolled 44 charts

Advanced Cancer

NCT00932451 2017-01-13

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Phase 2 Completed

1,069 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT00932893 2017-01-02

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Phase 3 Completed

347 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT00965731 2015-10-28

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

27 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01121575 2015-10-28

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

70 enrolled 50 charts